文献速递复苏、休克与脓毒症儿科与产科急症重症综合管理与镇静镇痛

间歇性与连续性ScvO2监测在儿童脓毒性休克中的随机非劣效性试验

'Intermittent' versus 'continuous' ScvO2 monitoring in children with septic shock: a randomised, non-inferiority trial.
PubMed 文献 · Intensive Care Med · 2019-11-28
一句话结论儿童脓毒性休克中,连续性ScvO2监测组6小时内休克缓解率高于间歇组(36% vs 19%),作者建议首选连续性监测滴定治疗。

该随机非劣效性试验纳入75例间歇组和77例连续性组年龄<17岁的脓毒性休克患儿,均置入锁骨下/颈内静脉导管并按拯救脓毒症运动指南管理,分别以间歇或连续ScvO2监测指导复苏。主要终点为6小时内达到治疗目标或休克缓解:间歇组19% vs 连续性组36%(RR 0.51,95%CI 0.29-0.89;风险差-18.0%,95%CI -32.0至-4.0),但置信区间下限跨过预设非劣效界值。24小时休克缓解率(63% vs 69%;RR 0.86,95%CI 0.68-1.08)和死亡率(47% vs 43%;RR 1.06,95%CI 0.74-1.51)两组无差异。作者结论认为,鉴于6小时内达到治疗终点比例更高,儿童脓毒性休克最初数小时应优先使用连续性ScvO2监测滴定治疗;无该条件时间歇监测也可使用。

要点

  • 儿童脓毒性休克6小时内休克缓解率:间歇ScvO2组19% vs 连续ScvO2组36%(RR 0.51,95%CI 0.29-0.89),连续组更高。
  • 6小时休克缓解的风险差为-18.0%(95%CI -32.0至-4.0),但置信区间下限跨过预设非劣效界值。
  • 24小时休克缓解率间歇组63% vs 连续组69%(RR 0.86,95%CI 0.68-1.08),无显著差异。
  • 死亡率间歇组47% vs 连续组43%(RR 1.06,95%CI 0.74-1.51),无显著差异。
  • 作者认为儿童脓毒性休克最初数小时应优先使用连续性ScvO2监测滴定治疗;无该条件时间歇监测也可使用。

适用人群与场景

  • 年龄<17岁的脓毒性休克患儿,随机分为间歇ScvO2组(75例)和连续ScvO2组(77例),中位年龄6岁(IQR 1.5-10)。
  • 所有患儿均置入锁骨下/颈内静脉导管,并按拯救脓毒症运动指南管理。

处置流程与药物剂量

  • 两组均按拯救脓毒症运动指南管理,以ScvO2结合其他临床和实验室参数指导复苏,其他参数监测两组相同。
  • 作者认为,儿童脓毒性休克最初数小时应优先使用连续性ScvO2监测滴定治疗。
  • 作者认为,无连续性监测条件时间歇监测ScvO2也可用于滴定治疗,因24小时休克缓解率和死亡率两组无差异。

研究设计与关键结果

  • 随机非劣效性试验,纳入间歇ScvO2组75例和连续ScvO2组77例脓毒性休克患儿,两组基线特征可比。
  • 主要终点6小时内休克缓解率:间歇组19% vs 连续组36%(RR 0.51,95%CI 0.29-0.89;风险差-18.0%,95%CI -32.0至-4.0),但置信区间下限跨过预设非劣效界值。
  • 24小时休克缓解率:间歇组63% vs 连续组69%(RR 0.86,95%CI 0.68-1.08),无显著差异。
  • 死亡率:间歇组47% vs 连续组43%(RR 1.06,95%CI 0.74-1.51),无显著差异。

证据类型、等级与局限

  • 证据类型:随机、非劣效性试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,儿童脓毒性休克最初数小时应优先使用连续性ScvO2监测滴定治疗,因6小时内达到治疗终点比例更高(36% vs 19%)。
  • 作者认为,无连续性ScvO2监测条件时,间歇监测可用于滴定治疗,因24小时休克缓解率和死亡率两组无差异。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: To compare the effect of 'intermittent' central venous oxygen saturation (ScvO2) monitoring with 'continuous' ScvO2 monitoring on shock resolution and mortality in children with septic shock.

METHODS: Primary outcome was the achievement of therapeutic goals or shock resolution in the first 6 h. We randomly assigned children < 17 years' age with septic shock to 'intermittent ScvO2' or 'continuous ScvO2' groups. All children were subjected to subclavian/internal jugular line insertion and managed as per Surviving Sepsis Campaign Guidelines. To guide resuscitation, we used ScvO2 estimated at other clinical and laboratory parameters were monitored similarly in both groups.

RESULTS: We enrolled 75 and 77 children [median (IQR) age: 6 (1.5-10) years] in the 'intermittent' and 'continuous' groups, respectively. Baseline characteristics were comparable between the groups. When compared to the 'continuous' group, fewer children in the 'intermittent' group achieved shock resolution within first 6 h [19% vs. 36%; relative risk (RR) 0.51; 95% CI 0.29-0.89; risk difference - 18.0%; 95% CI - 32.0 to - 4.0]. The lower bound of confidence interval, however, crossed the pre-specified non-inferiority margin. There was no difference in the proportion of children attaining shock resolution within 24 h (63% vs. 69%; RR 0.86; 95% CI 0.68-1.08) or risk of mortality between the groups (47% vs. 43%; RR 1.06; 95% CI 0.74-1.51).

CONCLUSIONS: Given that a greater proportion of children attained therapeutic end points in the first 6 h, continuous monitoring of ScvO2 should preferably be used to titrate therapy in the first few hours in children with septic shock. In the absence of such facility, intermittent monitoring of ScvO2 can be used to titrate therapy in these children, given the lack of difference in the proportion of patients achieving shock resolution at 24 h or in risk of mortality between the intermittent and continuous groups.

来源:Intensive Care Med,查看原文。版权归原作者所有。

参考来源

  1. Sankar J, Singh M, Kumar K, et al. 'Intermittent' versus 'continuous' ScvO2 monitoring in children with septic shock: a randomised, non-inferiority trial. Intensive Care Med. 2019. PMID: 31781836. doi:10.1007/s00134-019-05858-w

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。